Latest Industry Insights

Technology Networks recently spoke with Natalie Mount, CEO of Adaptate BioTherapeutics, to learn more about the company's aims and the challenges faced when developing immunotherapies and advancing them into clinical studies.

Recently, Thermo Fisher Scientific announced its membership of the Pistoia Alliance. At the Lab of the Future Congress 2019, we spoke with members of the Thermo Fisher team to learn more about the goals of joining the alliance, and what innovation means to Thermo Fisher.

As a stalwart in the biological and chemical analysis fields, JEOL celebrates its 70th anniversary this year. But that’s not all it is celebrating, with the appointment of 35-year veteran of JEOL USA, Bob Pohorenec as President of the company this year.

Trisha Rice, VP & GM Materials Science Business at Thermo Fisher Scientific, shares her experiences as a woman in science, and provides tips on how to be your most "authentic self" in the field.

Companion diagnostics (CDx), i.e. in vitro medical devices, and next-generation sequencing (NGS), are both essential to the practice of precision medicine. As new regulations are introduced, pharma companies and manufacturers alike need to ensure their CDx processes are compliant or we could see a deceleration in the flow of new precision therapies in the near future.

We recently had the pleasure of speaking with Danica Rankic, Associate Principal Scientist, MSD to learn more about their process chemistry activities. She touches on the synthesis strategies impacting drug discovery and provides a snapshot of her upcoming talk, taking place December, 2019.

We spoke to Daniel Rooke, Head of Operations and Legal at Start Codon, to learn more about the company and how they can help early stage healthcare and life science businesses in the UK to get off the ground.

We recently had the pleasure of interviewing Paul-Peter Tak, CEO of Kintai Therapeutics. Tak discusses how Kintai Therapeutics are exploiting the power of big data and machine learning to unravel the interconnected biology of the gut, and explains how the enteric signaling network can be therapeutically targeted.

In this article, Gary Kruppa, VP of Proteomics at Bruker Daltonics, explores how proteomic methods can help achieve the ultimate goal of preventing and improving the treatment of disease.

Biological complexity is not getting any easier to unravel but utilizing the power of computers could make us better at it.